<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2978">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813328</url>
  </required_header>
  <id_info>
    <org_study_id>SARS-CoV-2/helminth</org_study_id>
    <nct_id>NCT04813328</nct_id>
  </id_info>
  <brief_title>The Effect of Helminth Infection Plus COVID-19 Infection on the Immune Response and Intestinal Microorganisms</brief_title>
  <official_title>A Pilot Study of the Effects of Helminth Infection and SARS-CoV-2 Seropositivity on Immune Response and the Intestinal Microbiota in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, cross-sectional, sample collection study to characterize the immune response&#xD;
      and intestinal microorganisms in people with and without COVID-19 antibodies and helminth&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot, cross-sectional, sample collection study to characterize the immune response&#xD;
      and intestinal microbiota in people with and without SARS-CoV-1 antibodies and helminth&#xD;
      infection.&#xD;
&#xD;
      A target sample size of 600 participants aged 5 years or older will undergo a one-time blood&#xD;
      and stool collection for SARS-CoV-2 antibody testing, diagnosis of parasitic infections, and&#xD;
      experimental studies including transcriptomics (RNA) and microbiome (intestinal&#xD;
      microorganisms) characterization. Participants willing to take part in the study will be&#xD;
      selected from households in the Tiruvallur district, Tamil Nadu, India. Individual study&#xD;
      participation involves a single study visit. Participants will be informed of the results of&#xD;
      clinical testing and will be referred for medical care as appropriate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with helminth infections</measure>
    <time_frame>Day 1</time_frame>
    <description>Measured by qPCR diagnostics of stool DNA extraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with SARS-CoV-2 antibodies</measure>
    <time_frame>Day 1</time_frame>
    <description>Measured by real-time qPCR (quantitative polymerase chain reaction) assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with positive malaria test</measure>
    <time_frame>Day 1</time_frame>
    <description>Measured by fingerprick blood samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Differential blood count</measure>
    <time_frame>Day 1</time_frame>
    <description>Measured from venipuncture blood samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Hematocrit levels</measure>
    <time_frame>Day 1</time_frame>
    <description>Measured from venipuncture blood samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with latent tuberculosis infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Measured by IFN-Î³ release assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Wuchereria bancrofti infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Measured by enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Strongyloides stercoralis infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Measured by enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Ascaris infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Stool sample analysis via Kato-Katz microscopy, DNA extraction for qPCR and 16S sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with hookworm infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Stool sample analysis via Kato-Katz microscopy, DNA extraction for qPCR and 16S sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Strongyloides infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Stool sample analysis using Baermann technique, DNA extraction for qPCR and 16S sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Trichuris infection</measure>
    <time_frame>Day 1</time_frame>
    <description>Stool sample analysis using DNA extraction for qPCR and 16S sequencing</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COVID-19</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Coded PBMC, serum, stool RNA samples and data (without key to doe)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible participants will be enrolled from households in the Tiruvallur district, Tamil&#xD;
        Nadu, India. Villages and towns in the Tiruvallur district will be selected in consultation&#xD;
        with the Department of Public Health, Tamil Nadu. Areas that are known hotspots for&#xD;
        COVID-19 will be selected.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor venous access precluding venipuncture.&#xD;
&#xD;
          -  History of any illness or condition which, in the investigator's judgment, may&#xD;
             substantially increase the risk associated with the participant's participation in the&#xD;
             protocol, or compromise the scientific objectives.&#xD;
&#xD;
        Participants may be co-enrolled in other studies; however study staff should be notified of&#xD;
        co-enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subash Babu, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Research in Tuberculosis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P'ng Loke, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helminthiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

